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stimulation through cD40 and Tlr-4 
is an effective host Directed Therapy 
against Mycobacterium tuberculosis
Nargis Khan, Susanta Pahari, Aurobind Vidyarthi, Mohammad Aqdas and  
Javed N. Agrewala*
CSIR-Institute of Microbial Technology, Chandigarh, India
Tuberculosis (TB) is the leading cause of morbidity and mortality among all infectious 
diseases. Failure of Bacillus Calmette Guerin as a vaccine and serious side-effects and 
toxicity due to long-term TB drug regime are the major hurdles associated with TB con-
trol. The problem is further compounded by the emergence of drug-resistance strains 
of Mycobacterium tuberculosis (Mtb). Consequently, it demands a serious attempt to 
explore safer and superior treatment approaches. Recently, an improved understand-
ing of host–pathogen interaction has opened up new avenues for immunotherapy for 
treating TB. Although, dendritic cells (DCs) show a profound role in generating immunity 
against Mtb, their immunotherapeutic potential needs to be precisely investigated in 
controlling TB. Here, we have devised an approach of bolstering DCs efficacy against 
Mtb by delivering signals through CD40 and TLR-4 molecules. We found that DCs 
triggered through CD40 and TLR-4 showed increased secretion of IL-12, IL-6, and 
TNF-α. It also augmented autophagy. Interestingly, CD40 and TLR-4 stimulation along 
with the suboptimal dose of anti-TB drugs significantly fortified their efficacy to kill Mtb. 
Importantly, animals treated with the agonists of CD40 and TLR-4 boosted Th1 and 
Th17 immunity. Furthermore, it amplified the pool of memory CD4 T cells as well as 
CD8 T cells. Furthermore, substantial reduction in the bacterial burden in the lungs was 
observed. Notably, this adjunct therapy employing immunomodulators and chemother-
apy can reinvigorate host immunity suppressed due to drugs and Mtb. Moreover, it 
would strengthen the potency of drugs in curing TB.
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inTrODUcTiOn
Tuberculosis (TB) is one of the world’s most devastating disease killing 2 million people annually 
(1–3). Even though TB drugs are the backbone of current treatment that successfully eliminate 
Mycobacterium tuberculosis (Mtb); their efficacy is limited by a narrow therapeutic index and chronic 
toxicities. Furthermore, the situation has worsened due to emergence of drug-resistant strains of 
Mtb. Thus, it is considerably important to discover effective therapeutic stratagems to treat TB.
Since last two decades, the paradigm shift in the treatment of various diseases, preferably tumors 
and autoimmune diseases have evolved from chemotherapeutic agents to selective and mechanism-
based approaches (4). More recently, an improved understanding of host–pathogen interaction has 
given rise to new treatment options, which includes immunomodulatory approaches.
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Dendritic cells (DCs) are the most potent antigen-presenting 
cells (APCs) (5, 6). By virtue of their efficient antigen presen-
tation and elicitation of T cell response, several vaccination 
approaches have been developed to explore potency of DCs in 
enhancing the host immunity, particularly in the case of tumors 
(7). Noteworthy, tumors suppress DCs function to establish 
their growth (8, 9). However, DCs potent anti-tumor activity 
has been explored by reinvigorating their function by delivering 
signals through their surface receptors (7, 10). Consequently, 
indicating that impairment in the function of DCs can be 
restored. In addition to tumors, Mtb can also empower and 
impair the function of DCs (11). Mtb-infected DCs exhibit 
several deficiencies, including limited migration to draining 
lymph nodes, reduced lifecycle, and inferior bactericidal activ-
ity; thereby fail to elicit and impart protective immunity against 
Mtb (12, 13).
Dendritic cells express an array of costimulatory molecules, 
such as CD40, CD80, and CD86. These molecules can influ-
ence the activation of T cells and DCs (14). Furthermore, 
CD40 signaling can control the replication of viruses (15, 16). 
However, CD40 triggering can enhance the T cell response in 
Mtb-challenged mice but fails to reduce the bacterial burden 
in their lungs (17). This suggests that CD40 signaling needs 
some additional stimulator to enhance its efficacy. Toll-like 
receptors (TLRs) are known to amplify CD40-mediated 
immune response of DCs (7, 18, 19). The central role played by 
CD40 in eliciting acquired immunity is mirrored by TLR-4 in 
promoting innate immunity (20). Unlike other TLRs, TLR-4 in 
conjunction with CD40 maintains the persistence of IL-12 (7) 
that is crucial for the induction of Th1 immunity against Mtb. 
In addition, TLR-4 is a potent inducer of autophagy, which is 
a classical mechanism to restrict the intracellular survival of 
Mtb (21). Furthermore, it has been demonstrated that mac-
rophages infected with live Mtb shows upregulation of genes 
induced by MyD88-independent signaling pathway. Thereby, 
TLR-mediated responses to Mtb involve mostly MyD88-
independent pathway (22). Among all the TLRs, only TLR-4 
drives signal through both MyD88-dependent and -independ-
ent pathways (23). Therefore, combinatorial signaling through 
CD40 and TLR-4 may be a prudent step in bolstering the host 
immunity to limit Mtb growth.
Taking into consideration of the above-mentioned facts, 
we thought to explore CD40 and TLR-4 (C40.T4)-mediated 
signaling to boost host immunity. Furthermore, the concerted 
action of C40.T4 in association with anti-TB drugs to eliminate 
Mtb was also studied. In the present study, we demonstrate that 
triggering of Mtb-infected DCs through C40.T4 elicited T cell 
response, augmented the release of IL-6, IL-12, and TNF-α and 
reduced the intracellular bacterial burden. Interestingly, it was 
noticed that adjunct therapy employing CD40 and TLR-4 ago-
nists (C40.T4) significantly enhanced in vitro and in vivo killing 
potency of anti-TB drugs. The mechanism of augmented killing 
of mycobacterium in DCs was elucidated through involvement 
of autophagy. Thus, this study may open up new avenues of 
adjunct therapy employing drugs and C40.T4 to successfully 
treat TB.
MaTerials anD MeThODs
animals
C57BL/6 mice, 6–8  weeks were procured from the Institute of 
Microbial Technology (IMTECH), Chandigarh, India.
ethics statement
All experiments were approved by the Institutional Animal Ethics 
Committee of IMTECH and performed according to the National 
Regulatory Guideline issued by Committee for the Purpose of 
Supervision of Experiments on Animals (No. 55/1999/CPCSEA), 
Ministry of Environment and Forest, Government of India and 
Institutional Biosafety Committee.
antibodies and reagents
All the recombinant cytokines, antibodies (Abs) and ELISA rea-
gents were purchased from BD Biosciences (San Diego, CA, USA) 
and unless mentioned. TLR-4L (LPS EK ultrapure) was procured 
from Invivogen (San Diego, CA, USA). Abs for Western blotting, 
such as anti-mouse LC3 and anti-mouse inducible nitric oxide 
synthase (iNOS) Abs were purchased from Sigma (St. Louis, MO, 
USA) and AbCam (Cambridge, England), respectively.
culture of Bone Marrow-Derived  
Dendritic cells and Macrophages
Bone marrow-derived DCs were cultured according to the pro-
tocols adapted from Lutz et al. (24). Briefly, bone marrow cells 
(BMC) were flushed aseptically from femurs and tibia of mice. 
For DC culture, cells were grown in RPMI-1640 (Invitrogen 
Life Technologies, Eugene, OR, USA) containing FBS (10%) 
(GIBCO, Grand Island, NY, USA) with penicillin (100  U/ml), 
streptomycin (100 mg/ml), and l-glutamine (100 mM) and sup-
plemented with recombinant murine granulocyte-macrophage-
colony-stimulating factor (rGMCSF) (2 ng/ml) and recombinant 
murine interleukin (rIL)-4 (4 ng/ml). Cultures were maintained 
in a humidified atmosphere at 5% CO2/37°C. The medium was 
replenished after 3 days.
stimulation of BMDcs
On 6 days, BMDCs were incubated with biotin conjugated anti-
CD40 Ab (CD40A) or isotype control Abs (IgG2a,κ) (4 μg/106 
cells) for 30 min on ice followed by cross-linking with equivalent 
concentration of streptavidin, under similar conditions. The cells 
were washed and then plated in culture plates (5 × 105 cells/ml) 
containing either medium alone or medium containing TLR-4 
agonist (5  ng/ml). Suitable controls such as cells alone, cells 
stimulated with anti-CD40 Abs or isotype-matched Abs, with 
streptavidin or with TLR-4 agonist alone were also included in 
all experiments. For macrophages, BMC were grown in RPMI-
1640 +  FBS-10% and replenished with L929 supernatant (SN) 
(20%), as a source of macrophage-colony-stimulating factor 
(M-CSF). These cells were stimulated as described above for 
BMDCs.
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immunofluorescent staining
Dendritic cells harvested at 24 h were resuspended in FACS buffer 
(2% FBS, 2 mM sodium azide in PBS). To inhibit non-specific 
staining, cells were incubated with anti-CD16/32 Ab for 25 min 
at 4°C. Later, cells were stained with fluorochrome-conjugated 
Abs specific for mouse CD80, CD86, MHCII, or isotype-matched 
control Abs at a recommended concentration (0.5 μg/106 cells). 
The cells were fixed with 1× paraformaldehyde. Regular steps of 
washing were followed at each step. Data were collected using 
FACS ARIA and analyzed with the BD DIVA software. The inte-
grated MFI (IMFI) was calculated by multiplying the MFI with 
percentage of cells.
cytokines estimation
Cytokines viz IL-6, IL-12, TNF-α, and IFN-γ were detected in 
culture SNs at indicated time points (24 h) by standard ELISA, 
according to manufacturer’s instruction.
culturing of Mycobacterium
Mtb strains (H37Rv, H37Ra) were provided by Dr. VM Katoch, 
National JALMA Institute for Leprosy and Other Mycobacterial 
Diseases, Agra and GFP-H37Ra by Dr. P Gupta, IMTECH, 
Chandigarh, India. Mtb was cultured in Middlebrook 7H9 broth 
containing glycerol (0.2%) and Tween-80 (0.05%), supplemented 
with albumin, dextrose, and catalase. The viability of bacteria 
was determined by plating on Middlebrook 7H11 medium sup-
plemented with oleic acid, albumin, dextrose, and catalase and 
counting the number of colony-forming units (CFUs).
In Vitro infection with Mycobacterium
Dendritic cells and macrophages were infected with 
Mycobacterium smegmatis or Mtb at MOI 1:5 and harvested after 
3 or 4 h, respectively. The extracellular bacteria were removed by 
four to five times washing with 1× PBS. M. smegmatis and Mtb-
infected DCs were stimulated with C40.T4 [CD40A (4 μg/106 
cells) and TLR-4L (5  ng/ml)] and cultured in the presence of 
amikacin (2 μg/ml) for 16 or 24  h, respectively, in 48  W plate 
to kill extracellular bacteria. Where indicated, isoniazid (INH) 
(25 μg/ml) and rifampicin (RIF) (0.5 μg/ml) were added along 
with C40.T4.
cFUs Determination
Bacterial growth in DCs and macrophages was quantified after 
24 h of infection. Cell SNs were removed and 0.1% saponin was 
added to lyse the cells and plating was done with 10-fold serial 
dilution on 7H11 agar plate. The colonies were enumerated 
3 weeks after incubation at 37°C/5% CO2.
nitric Oxide Production
Supernatants of Mtb-infected DCs were harvested after 48 h of 
infection and nitric oxide (NO) was measured by Griess method 
(25, 26). Briefly, SNs (50 μl) were incubated with an equal volume 
of Griess reagent for 5 min at RT. Later, absorbance was measured 
at 550 nm.
antigen Uptake
Dendritic cells were stimulated with C40.T4 for 24 h. The cells 
were harvested, washed, and then pulsed with HRP (50 μg/ml). 
Antigen was chased for 30–60  min and uptake was arrested 
by adding chilled PBS (1×) followed by transferring cells on 
ice. Cells were washed extensively with ice cold PBS-FBS-1%. 
Subsequently, cells were lysed using Tris-HCl (10  mM) and 
Triton X-100 (0.05%) for 30 min on ice, with intermittent vortex-
ing. Intracellular HRP was estimated colorimetrically in the cell 
lysates using OPD-H2O2 chromogen-substrate. Concentration of 
HRP uptake was measured with respect to standard. Cells main-
tained at 4°C were used as control. HRP activity in test samples 
was suitably normalized with controls.
For confocal analysis, DCs were stimulated as mentioned 
above for 24 h. The cells were infected with GFP-Mtb (H37Ra) at 
(MOI 1:5) for 4 h, washed extensively (4×) with ice cold PBS (1×) 
and fixed with paraformaldehyde (4%). The cells were washed 
and placed on poly-l-lysine coated cover slips and imaged using 
Zeiss Confocal Laser microscope. Z-stacks were taken to exclude 
the interference of extracellular bacteria. Results were examined 
by image analysis software.
For bacterial uptake estimation through CFU, DCs were 
stimulated with C40.T4 for 24 h. Later, DCs were harvested and 
infection was given at MOI (1:5) for 4 h. It was followed by lysis 
of cells with 0.1% saponin and plating was done with 10-fold 
serial dilution on 7H11 agar plate. The colonies were enumerated 
3 weeks after incubation at 37°C/5% CO2.
cD40 and Beclin sirna Knock  
Down assay
Dendritic cells were incubated with ON TARGET plus CD40 
and beclin siRNA (Dharmacon, Chicago, IL, USA), according to 
manufacturer’s protocol. Briefly, DCs were incubated with CD40 
(20 nM) and beclin (20 nM) siRNA in serum-free media in the 
presence of transfection reagent 2 for 72 h. Later, level of inhibi-
tion in CD40 expression was estimated through flowcytometry 
and beclin at mRNA level by RT-qPCR. CD40 or beclin knock 
down DCs were infected with Mtb following the same protocol 
as mentioned above.
inhibition assay with nO inhibitor
Mtb-infected DCs were stimulated through C40.T4 in the pres-
ence or absence of iNOS inhibitor (N-monomethyl-l-arginine) 
(1 μM) for 24 h. Later, cells were lysed and CFU plating was done 
to quantify the viable bacteria.
expression of lc3 by Western Blotting
Dendritic cells were stimulated through C40.T4 for 2 h to detect 
LC3 and 18 h after Mtb infection for iNOS expression by Western 
blotting. Cells were washed and lysed with radioimmunopre-
cipitation assay (RIPA) buffer. Cellular extracts (40 μg protein) 
were subjected to SDS-polyacrylamide gel electrophoresis and 
transferred to a nitrocellulose membrane. Blots were incubated 
with anti-LC3 and iNOS Abs, followed by HRP-conjugated 
secondary Abs. Regular steps of incubation and washing were 
followed at each stage. Membranes were developed using a 
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chemiluminescent reagent and subsequently exposed to film 
(Pharmacia-Amersham, Freiburg, Germany). Starving DCs were 
used as positive controls.
expression of lc3 by 
immunofluorescence
Dendritic cells stimulated through C40.T4 were fixed on 
 poly-l-lysine coated cover slips for 15 min. Later, cells were fixed 
with paraformaldehyde (4×) for 10 min followed by treatment with 
Tween-20 (0.1%) for 30 s. To block non-specific sites, cells were 
incubated with BSA (5%) for 3 h, followed by rabbit anti-mouse 
LC3 Ab for 4 h. Subsequently, cells were incubated with anti-rabbit 
FITC for 1 h. Regular washings were done followed at each step. 
The cells were imaged through confocal microscopy. Starving DCs 
were also kept as positive control. Punctas were counted manually.
rT-qPcr for the Quantification of Beclin
Total RNA was isolated by Trizol reagent from DCs incubated 
with beclin siRNA according to the manufacturer’s instructions 
(Dharmacon, Chicago, IL, USA). RNA was quantified with the 
help of NanoDrop. A260/A280 ratio of all samples was in the range 
of 1.90–2.00. Intactness of RNA samples was determined with 
the help of formaldehyde denaturing agarose gel-electrophoresis. 
DNA contamination from RNA samples was removed by ampli-
fication grade DNase (Sigma, St Louis, MO, USA). Briefly, RNA 
samples (1 μg) were incubated with DNase (1U) for 15 min in the 
reaction buffer. After the incubation, DNase activity was termi-
nated by stop solution (Sigma, St Louis, MO, USA). Furthermore, 
the samples were heated to 70°C for 10 min to inactivate DNase 
activity. Results are represented in the form of re-expression (fold) 
relative to untreated controls. Analysis was done by comparative 
Ct method, whereas Ct values were normalized against house-
keeping control actin. RT-qPCR and data analysis were done by 
Realplex Mastercycler (Eppendorf, Hamburg, Germany).
Therapeutic strategy
Mice were aerosol challenged with Mtb for the deposition of 
100 CFUs in lungs. At 24 h after aerosol challenge, three mice 
were sacrificed for quantification of pathogen delivery to lungs 
by measuring CFU in lung homogenates. Mice were found 
to be infected with the 100–120 CFU of H37Rv in their lungs. 
After 21 days, animals were administered twice with the CD40A 
(50 μg/300 μl/mouse) in conjunction with TLR-4L (1 μg/300 μl/
mouse) (C40.T4) i.p. with an interval of 15 days (18). The control 
groups were injected with either CD40A (50 μg/300 μl/mouse) 
or TLR-4L (1 μg/300 μl/mouse) or placebo (PBS). After 50 days 
of aerosol challenged, animals were sacrificed and the bacterial 
burden was enumerated in the lungs by CFU counting.
isolation of lymphocytes and  
Phenotypic analysis
Mice were treated with C40.T4 or controls with CD40A or 
TLR4L or PBS after 21  days of aerosol challenged with Mtb. 
Fifty days later, mice were sacrificed. The animals were perfused 
with cold PBS-heparin and spleen and mediastinal lymph nodes 
were harvested and single cell suspension was prepared. Briefly, 
lymphocytes from spleen were prepared by lysing RBCs with 
ACK lysis buffer (NH4Cl 0.15 M, KHCO3 10 mM, EDTA 88 mM), 
washed 3× with PBS and resuspended in RPMI-1640-FBS-10%. 
Viability of the cells was assessed by trypan blue dye-exclusion 
method. The experiments were performed to detect intracellular 
cytokines and effector/central memory markers on T cells upon 
in vitro restimulation with purified protein derivative (PPD).
adoptive Transfer of cD4 T cells and cD8 
T cells into sub-lethally irradiated Mice
Splenocytes of Mtb-challenged mice treated with C40.T4 were 
in  vitro stimulated with PPDs to expand Mtb reactive T cells. 
Later, CD4 T cells and CD8 T cells were purified by negative 
selection using MACS sorter, as per manufacturer’s instructions 
(BD Biosciences, San Diego, CA, USA). CD4 T cells or CD8 
T cells (5 × 106) were administered into recipient mice after 24 h 
of sub-lethal irradiation (500R). Within 24  h of cell transfer, 
recipient mice were aerosol challenged with Mtb (27).
For in vitro assay, purified CD4 T cells and CD8 T cells isolated 
as mentioned above were co-cultured with Mtb-infected DCs for 
48 h. Later, cells were lysed with 0.1% saponin and plating was 
done with 10-fold serial dilution on 7H11 agar plate. The colonies 
were enumerated 3 weeks after incubation at 37°C/5% CO2.
statistical analysis
The GraphPad Prism software program was used to perform all 
statistical analysis. Statistical testing was performed by one way 
ANOVA for group analysis and Student’s t-test for comparing 
two groups. Differences were considered significant at a level of 
p < 0.05.
resUlTs
signaling through c40.T4 induced the 
Maturation and activation of Dcs
Although, signaling to DCs was delivered through CD40, CD80, 
and CD86 molecules but CD40-stimulated DCs exhibited 
optimal activation (Figure S1A in Supplementary Material). 
Furthermore, CD40-mediated signaling was significantly ampli-
fied in conjunction with TLR-4 (Figure S1B in Supplementary 
Material). Hence, in the subsequent experiments, CD40 and 
TLR-4 (C40.T4) were used to activate DCs. We used Abs to 
CD40 (CD40A) and highly pure LPS (EK ultrapure) as an agonist 
for TLR-4 (TLR-4L) signaling. The optimum concentration of 
CD40A (4 μg/106 cells) and TLR-4L (5 ng/ml) was selected on 
the basis of dose-dependent response in releasing IL-6 and IL-12 
(Figure S1B in Supplementary Material). IL-6 and IL-12 are the 
major cytokines produced by DCs in response to infection by 
intracellular pathogens. These cytokines have potent effect on 
T cells activation and other cells of immune system. Therefore, 
they are considered as an important bridge between innate and 
adaptive immunity. Upregulation of costimulatory molecules is a 
characteristic feature of mature DCs (28). Interestingly, DCs trig-
gered through C40.T4 showed significant enhancement in IMFI 
of CD80 (p < 0.05), CD86 (p < 0.05) and MHCII (p < 0.05) mol-
ecules (Figures S1C–E in Supplementary Material). No change 
FigUre 1 | signaling through c40.T4 enhanced the production of cytokines and expression of cD80, cD86, and Mhcii on Mtb-infected Dcs. 
Mtb-infected DCs were stimulated through C40.T4 for 24 h. Control cultures were also set using CD40A, TLR4L, isotype-matched controls, and medium alone. 
Later, SNs were harvested for the detection of (a) IL-6; (B) IL-12; (c) TNF-α; (D) IL-10 by ELISA and expressed as pg/ml. Data shown as mean ± SD are 
normalized with their respective isotype-matched controls. CD11c+ DCs were phenotyped by flowcytometry for the expression of (e) CD80 (p < 0.001); (F) CD86 
(p < 0.01); (g) MHCII. Data expressed as mean ± SD of percent positive cells are representative of three independent experiments. “*,” “**,” and “***” indicate 
p < 0.05, p < 0.01, and p < 0.001, respectively.
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was observed with isotype-matched control Abs of CD40. It was 
of concern for us whether the influence of signaling through C40.
T4 is restricted to DCs alone or can stimulate the macrophages as 
well. Similarly, we observed that triggering C40.T4 substantially 
(p <  0.01) enhanced the production of IL-6 by macrophages 
(Figure S2A in Supplementary Material).
The aim of the current study was to activate Mtb-infected 
DCs through C40.T4 and, consequently, to control the 
growth of the pathogen. We observed that C40.T4 stimulation 
improved the potency of infected DCs to produce cytokines, 
such as IL-6 (p  <  0.001), IL-12 (p  <  0.0001), and TNF-α 
(p  <  0.001) (Figures  1A–C). No change was noted in IL-10 
FigUre 2 | c40.T4 augmented the antigen uptake capacity of Dcs. (a) C40.T4 stimulated DCs were pulsed with antigen HRP for 60 min. Cells were washed 
and lysed to measure HRP uptake by colorimetry. Values were normalized with experimental blank and control cells kept on ice. (B) C40.T4 activated DCs were 
co-cultured with GFP-expressing Mtb (gMtb) for additional 4 h and were imaged through confocal microscopy. Each image represents the cells from three different 
fields. (c) C40.T4 activated DCs were infected with Mtb for 4 h. Later, mycobacterial uptake was enumerated by CFUs plating. Results are expressed as 
mean ± SD (a,c). Data are the representative of three individual experiments. “*” and “**” indicate p < 0.05 and p < 0.01, respectively.
6
Khan et al. CD40/TLR-4 Stimulation Controls Mtb
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 386
(Figure  1D). Similarly, infected macrophages stimulated with 
C40.T4 augmented the secretion of IL-6 (p < 0.05) (Figure S2B 
in Supplementary Material). Furthermore, Mtb-infected DCs 
stimulated through C40.T4 expressed considerably higher 
levels of costimulatory molecules CD80 (p <  0.01) and CD86 
(p < 0.01), as compared to control (Figures 1E–G). However, not 
much change was observed in the expression of MHCII. It may 
be due to saturation in the expression of MHCII on DCs upon 
infection with Mtb.
Dendritic cells are highly efficient in antigen uptake (28). 
Therefore, we next studied whether the C40.T4 stimulation 
enhanced the capacity of DCs for antigen uptake. Interestingly, 
C40.T4 signaling showed significant (p < 0.05) augmentation in 
the antigen (HRP) uptake as observed by colorimetric method 
(Figure  2A). It is known that DCs endocytose HRP chiefly 
through fluid phase pinocytosis driven by constitutive membrane 
ruffling activity and traces of it is taken up by receptor-mediated 
endocytosis (29, 30). It suggests that DCs activated through C40.
FigUre 3 | signaling delivered through c40.T4 potentiate Dcs ability to restrict Mtb growth. DCs were infected with mycobacterial strains H37Ra, H37Rv, 
and M. smegmatis followed by stimulation through C40.T4 for 24 h. Later, mycobacterial survival was enumerated by CFUs plating for (a) H37Rv on 21 days;  
(B) H37Ra on 21 days; (c) M. smegmatis on 3 days. Data are represented as the mean ± SD of three independent experiments. “*” indicate p < 0.05.
7
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T4 stimulation exhibited substantial enhancement in HRP uptake 
through pinocytosis. Furthermore, we studied the phagocytic 
ability of DCs by confocal microscopy and CFU plating assay. 
Our results demonstrate higher uptake of GFP+Mtb by DCs upon 
stimulation through C40.T4 and noteworthy (p < 0.05) increase 
in the Mtb uptake by confocal microscopy and CFU plating, 
respectively (Figures 2B,C). These results suggest that the signal-
ing of DCs through C40.T4 improves their endocytic capacity.
c40.T4 Triggered Dcs efficiently 
constrained the intracellular  
survival of Mtb
Next, we were interested to study the effect of C40.T4 on the 
bactericidal activity of DCs. Mtb-infected DCs were triggered 
through C40.T4 for 24  h. We observed enhanced bactericidal 
activity of C40.T4 stimulated DCs, as evidenced by significant 
killing of virulent strain (H37Rv) of Mtb (p  <  0.05). These 
results were further substantiated using non-virulent strains 
of mycobacteria, such as H37Ra (p < 0.05) and M. smegmatis 
(p < 0.05) (Figures 3A–C). Not much change was observed in 
CD40 or TLR-4 or isotype-matched controls. Similar results 
were observed in the case of macrophages (Figure S2C in 
Supplementary Material). It is important to mention that the 
difference in uptake of Mtb as shown in (Figure  2C) had no 
impact on their bactericidal activity. In the case of phagocytic 
assay, DCs were first stimulated with C40.T4 and then infected 
with Mtb. By contrast, bactericidal activity of DCs was demon-
strated by first infecting them with Mtb and then stimulating 
through C40.T4.
Dcs Deficient in cD40 and Tlr-4 Fails  
to restrict the growth of Mtb
It was quite important for us to check the specificity of signals 
delivered through CD40 and TLR-4. CD40 gene in DCs was 
knock down by siRNA (CD40KD). Efficacy of the assay, as 
observed by flowcytometry, was 60% (Figures 4A,B). In addition, 
FigUre 4 | Knockdown of cD40 in the presence of Tlr-4 inhibitor (Tlr-4i) establishes the specificity of signaling delivered through c40.T4 in 
inhibiting the survival of Mtb. DCs were treated with CD40 siRNA (CD40si) for 48 h. Expression of CD40 on DCs was monitored by flowcytometry. Number in 
histograms indicates the percentage of CD40 negative population of DCs (a) wild-type cells; (B) CD40 knock down cells. (c) CD40 knock down and wild-type DCs 
were infected with Mtb followed by stimulation through C40.T4 in presence or absence of TLR-4i for 24 h. Later, cells were lysed and bacterial burden was 
enumerated on 21 days by CFU counting. Data shown are mean ± SD and representative of two independent experiments. CD40si: CD40 knockdown by SiRNA; 
TLR-4i: TLR-4 inhibitor.
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the specificity of TLR-4 signaling was established using TLR-4 
inhibitor (TLR-4i) CLI-095. Next, CD40KD DCs infected with 
Mtb were stimulated with CD40A and TLR-4L in the presence 
or absence of TLR-4i. Interestingly, such CD40KD DCs cultured 
in the presence of TLR-4i followed by their stimulation through 
C40.T4 showed no decline in the growth of Mtb, when compared 
with Mtb-infected DCs triggered through C40.T4. We also 
observed no change in the control DCs with or without mock 
transfection (Figure  4C). Hence, establishing the specificity of 
these experiments.
FigUre 5 | c40.T4 triggering enhances the potency of riF and inh to kill intracellular Mtb. DCs infected with Mtb were stimulated through the indicated 
combinations of C40.T4, CD40, TLR-4 with (a) RIF (24 h) (B) INH (24 h); (c) RIF (0–72 h). Later, cells were lysed and CFUs were monitored on 21 days. Data 
represented as mean ± SD (a–c) are of three independent experiments. “*,” “**,” and “***” indicate p < 0.05, p < 0.01, and p < 0.001, respectively.
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adjunct Therapy with c40.T4 and anti-TB 
Drugs substantially enhances Bactericidal 
Potency of Dcs
The lengthy drug-regime for treating TB patients not only inflicts 
side-effects but also other serious problems like emergence of 
drug-resistant strains of Mtb. Therefore, we hypothesized to 
explore adjunct therapy with drugs in combination with immu-
nomodulators to minimize the dose and duration of anti-TB 
drugs and increase their bactericidal activity. Mtb-infected DCs 
activated through C40.T4 considerably bolstered the  bactericidal 
potency of anti-TB drugs RIF (p < 0.001) and isoniazid (p < 0.05), 
in comparison to drugs alone (Figures 5A,B). It may be concluded 
from these results that adjunct therapy of boosting immunity via 
CD40 and TLR-4 may be an important strategy to enhance the 
killing efficacy of drugs.
Importantly, our time kinetics study established that adjunct 
therapy employing immunomodulators and drugs could sub-
stantially reduce the duration of drug regime for killing Mtb 
(Figure 5C). Mtb-infected DCs activated through C40.T4, upon 
10
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treatment with RIF exhibited reduction in the intracellular 
burden of Mtb (1.8 × 105 to 1 × 105) at a significantly lesser time 
(16 h) than treatment with RIF alone (72 h) (Figure 5C). Thus, 
our observation establishes the importance of adjunct therapy 
utilizing CD40A and TLR-4L along with drugs. This adjunct 
therapy could be further explored as immunotherapeutic regi-
men for reducing the duration of TB treatment.
c40.T4 induced Bactericidal Mechanism  
is autophagy Dependent
Involvement of NO is a classical mechanism related with the 
killing of intracellular pathogens. Hence, we thought to monitor 
the change in the NO secretion. Importantly, magnitude of NO 
secretion was significantly (p < 0.01) enhanced in Mtb-infected 
DCs triggered through C40.T4, as compared to untreated or 
CD40 or TLR-4 triggered DCs (Figure  6A). Furthermore, our 
Western blotting experiments also showed considerable enhance-
ment in the expression of iNOS (Figure S3A in Supplementary 
Material). We confirmed the specificity of NO on the survival 
of Mtb by culturing C40.T4 activated DCs with iNOS inhibi-
tor (N-monomethyl l-arginine). We observed the recovery of 
viable bacteria in the presence of iNOS inhibitor (Figure S3B in 
Supplementary Material). However, only marginal restoration 
in the survival of Mtb was achieved, indicating the involvement 
of an additional mechanism. Hence, we thought to monitor 
autophagy, which is considered to be quite crucial in inhibiting 
the intracellular survival of Mtb (31, 32). Intriguingly, C40.T4 
triggered DCs exhibited significantly higher conversion of LC3I 
to LC3II, a hallmark phenomenon of autophagy (Figure 6B). This 
information was corroborated with intracellular LC3 staining for 
puncta formation (Figures 6C–E). Furthermore, acidic vacuoles 
were stained with acridine orange dye to show the induction of 
autophagy (Figure 6F). In addition, we have knocked down the 
expression of beclin in DCs through siRNA prior to Mtb infection 
(Figure S3C in Supplementary Material). We observed that beclin 
knock down DCs if triggered through C40.T4 fails to restrict 
the Mtb growth (Figure  6G). These results suggest that C40.
T4-induced autophagy significantly contributes in constraining 
the Mtb growth.
immunization with c40.T4 Bolstered  
the immune response and reduced  
Mtb Burden in Mice
Finally, we used this strategy in the experimental model of TB. 
The animals were aerosol challenged with Mtb and 21  days 
later inoculated with CD40A and TLR-4L. After 50 days, mice 
were sacrificed. The cells were isolated from the lungs and 
spleen and cultured with PPD for 48 h. Later, we monitored the 
expression of activation markers viz. CD44 and CD69 on CD4 T 
cells. Interestingly, we observed that animals injected with C40.
T4, displayed higher levels of CD44 and CD69 on CD4 T cells 
(Figures 7A–D). Similar results were noted in the case of CD8 
T cells (Figure 7B). Control groups constituting of individually 
administered CD40A or TLR-4L showed marginal change in the 
expression of activation markers. It implies the importance of 
synergism between C40.T4 molecules in reinvigorating immu-
nity during Mtb infection.
CD4 T cells and CD8 T cells are crucial in providing protec-
tion against Mtb (33). IFN-γ released by CD4 and CD8 T cells 
play a pivotal role in restricting the growth of Mtb (34).  IFN-γ–/– 
mice are fatally susceptible and humans deficient for IFN-γ or 
IFN-γR are prone to Mtb infection (35). Although, IFN-γ is 
necessary for immunity against TB, but its presence alone is not 
sufficient for protection. Recently, IL-17 has been proven to be 
efficient in reducing the bacterial burden (36, 37). Therefore, we 
examined the expression of IFN-γ and IL-17. Mice inoculated 
with anti-CD40 Abs and TLR-4L showed predominance of 
Th1 and Th17 response on in  vitro stimulation with PPD, as 
evident by significantly higher production of IFN-γ (p < 0.05) 
and IL-17 (p  <  0.05), respectively (Figures  7E–G). Similar 
results were noted for IFN-γ (p < 0.01) release by CD8 T cells 
(Figure 7F). Furthermore, we observed significant upregulation 
in the expression of CD86 (p < 0.05) and CD40 on DCs isolated 
from the lungs of Mtb-infected animals injected with C40.T4 
(Figures 7H,I).
Next, we monitored the CFU burden in the lungs of C40.T4 
treated mice. We observed significant (p < 0.01) decline in the 
mycobacterial burden compared to control mice treated with 
PBS, TLR-4L and CD40A (Figure  8A). Furthermore, the data 
were validated by histopathology samples. We observed that C40.
T4 treated lungs showed less granulomatous lesions. The lungs 
were less consolidated with more normal alveolar structures. The 
number of granulomas were decreased in the lungs of C40.T4 
immunized mice, as compared to placebo control (Figure 8B). 
These experiments showed the potential of C40.T4 immuno-
therapy in boosting the immunity of the Mtb-infected animals 
along with reduction in the bacterial load.
adoptive Transfer of cD4 and cD8 T cells 
showed significant reduction in Mtb 
Burden
Next, we have demonstrated the vis-à-vis role of CD4 T cells 
and CD8 T cells in limiting Mtb growth. Hence, we purified 
CD4 T cells and CD8 T cells from Mtb aerosol challenged 
mice treated with C40.T4 and adoptively transferred in sub-
lethally γ-irradiated animals. Mice were aerosol challenged 
with Mtb. After 15 days, animals were sacrificed and significant 
reduction (p < 0.05) in the bacterial load in the lungs of mice 
was noticed. Similar results were observed with CD8 T cells 
(p < 0.001) (Figure 8C). Likewise, to prove the influence more 
precisely, CD4 T cells and CD8 T cells were co-cultured with 
Mtb-infected DCs. We observed significant decline in the CFUs 
in cultures incubated with CD4 T cells (p < 0.05) and CD8 T 
cells (p <  0.05) (Figures S4A,B in Supplementary Material). 
These results suggest that C40.T4 triggering augments the T 
cell response, which contributes in inhibiting the growth of 
bacterium.
c40.T4 adjunct Therapy with inh 
significantly Potentiates In Vivo efficacy 
of inh in restraining the growth of Mtb
Mtb-infected mice treated with INH in conjunction with C40.
T4 showed significant (p < 0.001) reduction in the mycobacterial 
FigUre 6 | Triggering through c40.T4 showed augmentation in autophagy. DCs infected with Mtb were stimulated through C40.T4, CD40, TLR-4 for 24 h 
and assessed for (a) NO in SNs by Greiss assay. (B) Expression of LC3 was detected in the whole cells lysates of DCs stimulated for 2 h through C40.T4 by 
immunoblotting. Actin was used as a loading control. Densitometric data show the LC3I/actin and LC3II/actin ratio. (c) LC3 puncta formation was demonstrated by 
immunofluorescence staining. Starved DCs were used as a positive control; (D,e) Bar graphs depict the percentage of LC3 puncta positive cells and LC3 puncta 
per cells, respectively. (F) DCs were stimulated through C40.T4 for 5 h were later incubated with acridine orange for 15 min to visualize autophagosomes by 
fluorescence microscopy (40×). Orange dots indicate the acidic vacuoles. (g) BeclinKD DCs were infected with Mtb followed by stimulation with C40.T4. Later, cells 
were lysed and bacterial burden was quantified by CFU assay. Data represented as the mean ± SD (a,D,e,g); immunoblotting (B); fluorescent microscopy (c,F); 
are of 2–3 independent experiments. “*” and “**” indicate p < 0.05 and p < 0.01, respectively.
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FigUre 7 | c40.T4 treatment bolstered the T cells immunity in mice exposed to Mtb. Mtb-infected animals were administered C40.T4. After 50 days, mice 
were sacrificed and lymphocytes were isolated and cultured with purified protein derivative (6 μg/ml) for 48 h. Later, cells were stained for the expression of  
(a) CD44/CD69 on CD4 T cells isolated from the lungs; (B) CD44/CD69 on CD8 T cells isolated from the lungs; (c,D) CD44/CD69 on CD4 T cells isolated from the 
spleens. Number in the histograms indicates the percentage of CD44hi and CD69hi on CD4 and CD8 gated population. Splenocytes stimulated in vitro with PPD 
were stained for expression of (e) IFN-γ on CD4 T cells; (F) IFN-γ on CD8 T cells; (g) IL-17 on CD4 T cells. The bar diagrams illustrate percent population and 
results expressed as mean ± SD. DCs isolated from the lungs of Mtb-infected animals treated with C40.T4 were stained for the expression of (h) CD40; (i) CD86 
and on CD11c + DCs. Number in the histogram indicates the mean ± SD of CD11c+ DCs expressing CD40 and CD86 population. The data are representative of 
two independent experiments (n = 4 mice/group). “*,” “**,” and “***” indicate p < 0.05, p < 0.01, and p < 0.001, respectively.
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FigUre 8 | immunomodulation through c40.T4 reduces the bacterial burden in the lungs of Mtb-challenged mice and enhances the potency of 
isoniazid. (a) Mice infected with Mtb were immunized with C40.T4. Later, animals were sacrificed and mycobacterial load in the lungs was enumerated by CFUs 
plating; (B) Photomicrographs (40×) of H & E stained lung sections. (c) CD4 and CD8 T cells were purified from C40.T4 treated and Mtb-challenged mice. Later, 
CD4 or CD8 T cells were adoptively transferred into sub-lethally irradiated mice. After 12 h, mice were aerosol challenged with Mtb. The bacterial burden in the lungs 
was enumerated on 15 days by CFUs plating. Labeling of “x” axis signifies CD4 or CD8: adoptive transfer of either CD4 or CD8 T cells isolated from Mtb-challenged 
mice; C40.T4.CD4 or C40.T4.CD8: adoptive transfer of either CD4 or CD8 T cells isolated from Mtb-challenged and C40.T4-treated mice. (D) Animals infected with 
Mtb were administered with C40.T4 and two doses of INH (INH5: 5 mg/kg bwt, INH25: 25 mg/kg bwt of mouse). Later, mice were sacrificed and mycobacterial 
load was enumerated in the lungs by CFUs plating. Data represented as mean ± SEM are from two independent experiments with (n = 4mice/group). Control 
groups of mice were administered PBS, CD40A, TLR-4L. “IC”: isotype control. “*,” “**,” and “***” indicate p < 0.05, p < 0.01, and p < 0.001, respectively.
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load in the lungs (Figure  8D). Most importantly, the dose of 
5 mg/kg bwt of INH administered to mice as an adjunct therapy 
with C40.T4 imparted considerably (p < 0.05) better decline in 
the CFUs, as compared to 25 mg/kg bwt of INH alone. It is worth 
to mention here that the C40.T4 + INH was administered only 
twice over a period of 30 days after Mtb challenge. These results 
support our hypothesis that C40.T4 significantly reduces the dose 
of anti-TB drug INH.
DiscUssiOn
Dendritic cells are the bridging component of both innate and 
adaptive immunity and their function is regulated by their dif-
ferentiation, maturation, and activation status (38). However, in-
spite of their sentinel role in eliciting immune response, DCs role 
is limited due to their suboptimal maturation in vivo in certain 
diseases, such as cancer and AIDS (39). Furthermore, pathogens, 
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such as Mtb, leishmania, cancer, etc., hamper their function and, 
therefore, paralyze the immune system (11). Therefore, to boost 
the immune response, it is quite crucial to rescue DCs from 
pathogens or tumors that interfere in their performance.
CD40 in conjunction with TLR-4 has been reported in 
substantially augmenting DCs activity to regress tumor growth 
and optimally activate T cells (7, 10, 19). Thus, indicating the 
immunotherapeutic potential of C40.T4 in bolstering the func-
tion of DCs and thereby systemic immunity. To the best of our 
knowledge, the role of C40.T4 has not been monitored in any 
infectious disease. Henceforth, we investigated the combinato-
rial role of C40.T4 in the activation of DCs, thus hampering the 
growth of Mtb. We also studied the immunotherapeutic potential 
of C40.T4 as an adjunct therapy with anti-TB drugs INH and 
RIF to reduce the dose and duration of the TB drug regimen in 
influencing the survival of Mtb. Following major findings have 
emerged from this study when signaling of DCs was delivered 
through C40.T4 (i) upregulation of the activation markers CD80, 
CD86, MHCII; (ii) robust production of IL-6, IL-12, TNF-α; (iii) 
augmented ability of DCs to phagocytose antigen; (iv) enhanced 
lung immunity and reduced Mtb burden; (v) significant decrease 
in the dose and duration of the drugs and increment in their 
bactericidal potency.
Our in vitro data demonstrate the role of signaling delivered 
through C40.T4 in the activation of Mtb-infected DCs. DCs are 
inferior in bactericidal activity and, therefore, boosting their 
killing efficacy will strengthen their function. The phenotypic 
markers of C40.T4 triggered DCs (TNF-αhi, IL-12hi, IL-6hi) indi-
cated that they acquired enough potential to kill Mtb. Mtb infects 
both DCs and macrophages (40). Similar to DCs, infected mac-
rophages also restrict the growth of Mtb by activating bactericidal 
mechanism, such as NO production. In addition, macrophages 
are the major contributor in forming the structured granulomas, 
responsible in controlling the Mtb growth (41). Therefore, it is 
important to bolster the function of macrophages to control 
Mtb growth. Noteworthy, C40.T4 signaling also augmented the 
bactericidal activity of macrophages, as evidenced by restriction 
in the intracellular survival of Mtb (Figure S2C in Supplementary 
Material), but need further investigation to elucidate the mecha-
nism adapted by CD40 and TLR-4 macrophages to kill Mtb.
To establish infection, Mtb evades the immune mechanism. 
Blocking of phago-lysosome fusion is one of the strategies utilized 
by Mtb to hampers the antigen presentation by DCs and mac-
rophages (42). Henceforth, it is important to design strategy that 
can overcome the inhibition in phagolysosme fusion. Autophagy 
is a phenomenon that targets the cytoplasm content and damaged 
organelle to autophagosome, which in turn fuse with lysosome. 
In addition, autophagy and NO are considered to be major path-
ways involved in the clearance of array of pathogens, including 
Mtb (31, 43). Interestingly, CD40 and TLR-4 signaling showed 
augmentation in autophagy and marginal increase in NO release.
Th1 cells confer protective immunity against Mtb through 
production of effector cytokine IFN-γ. In addition, Th17 cells 
protect against Mtb (44). Besides IFN-γ, current vaccination 
strategies for TB also show the importance of IL-17 cytokine 
(45). More interesting findings came out with the observation 
that IL-17 is crucial to induce protection in hyper-virulent but not 
lesser-virulent strains of Mtb (36). Noteworthy, administration 
of C40.T4 in Mtb-challenged animals augments Th1 and Th17 
response. It suggest that increase in the production of both IFN-γ 
and IL-17 with C40.T4 administration may play a vital role in 
generating protective immunity against clinical isolates of Mtb.
Though, our in  vitro data support that C40.T4 induces the 
activation of DCs and macrophages but improved host immunity 
in infected animals could be an outcome of involvement of many 
other cells. Since, B cells also express CD40 and recently B cells 
have been shown to regulate the level of granulomatous reaction, 
cytokine production, and T cells response (46). It needs further 
investigation that how other cells respond to CD40 and TLR-4 
signaling in  vivo and may contribute in mediating protection 
against Mtb.
In addition, we monitored the role of C40.T4 as an adjunct 
therapy with anti-TB drugs in curbing the growth of Mtb. 
Although, current TB drug regime is extremely efficient but the 
major impediment is long-duration of at least 6-month treatment. 
Therefore, inevitably giving rise to several side-effects and provid-
ing ample time to mycobacterium in developing drug resistance 
(47). Nevertheless, remarkable potency of TB drugs still cannot be 
overlooked. A number of studies have been attempted to enhance 
the efficacy of TB drugs for better outcome and were considered 
beneficial (48). Based on published reports with potential role 
of CD40 and TLR-4 in other disease models, we explored them 
in reinforcing the host immunity against Mtb (7). Furthermore, 
the added advantage of C40.T4 immunotherapy was that it sig-
nificantly decreased the dose of anti-TB drugs. Animals delivered 
fivefold lesser dose (5  mg/kg/bwt) of INH bimonthly showed 
significant reduction in the bacterial burden in the lungs, against 
the recommended daily treatment of 25 mg/kg/bwt (49). There is 
a fundamental advantage of INH-C40.T4 adjunct therapy since 
the drug would kill the replicating Mtb and C40.T4 would take 
care of drug induced immunosuppression and also adjuvantage 
host immunity to kill non-replicating quiescent microorgan-
ism. Furthermore, INH-C40.T4 strategy will be beneficial in 
(i) subsiding the drug inflicted side-effects because of low dosage; 
(ii) modulating host immunity; (iii) restraining the emergence 
of drug-resistance; and (iv) reducing the dose and duration of 
the drug regime. The idea of implementing this approach of 
drug as an adjunct therapy with immunomodulators to kill Mtb 
and concurrently bolstering host-immunity may pave a way for 
designing immunotherapeutic strategy to effectively control TB.
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